|1.||Pfoh, Roland: 1 article (01/2008)|
|2.||Schuster, Heiko J: 1 article (01/2008)|
|3.||Tietze, Lutz F: 1 article (01/2008)|
|4.||Rühl, Stephan: 1 article (01/2008)|
|5.||Hampel, Sonja M: 1 article (01/2008)|
|6.||Sugiyama, Hiroshi: 1 article (01/2007)|
|7.||Teraoka, Hirobumi: 1 article (01/2007)|
|8.||Fujiwara, Tsuyoshi: 1 article (01/2007)|
|9.||Hirota, Mikako: 1 article (01/2007)|
|10.||Mineshita, Satoru: 1 article (01/2007)|
01/01/2008 - "(1S,10R)-9 is the key intermediate in the synthesis of the prodrug 2, which has been developed for a selective treatment of cancer based on the antibody-directed enzyme prodrug therapy as an analogue of the natural antibiotic duocarmycine SA (1)."
01/01/2008 - "Enantio- and diastereoselective synthesis of duocarmycine-based prodrugs for a selective treatment of cancer by epoxide opening."
06/01/2002 - "KW-2189, a semisynthetic duocarmycine antibiotic has been shown to exert antiproliferative effects against human tumor cell lines in vitro and animal tumor models in vivo. "
01/01/2007 - "Distamycin A enhances the cytotoxicity of duocarmycin A and suppresses duocarmycin A-induced apoptosis in human lung carcinoma cells."
12/01/1994 - "Duocarmycin A (DUMA) and DU-86, a semisynthetic derivative of duocarmycins (DUMs) and a possible active form of KW-2189, both showed potent cell growth-inhibitory and cell-killing activities against human uterine cervix carcinoma HeLa S3 cells. "
|3.||DNA (Deoxyribonucleic Acid)